Therapeutic Strategies for Targeting TAMs in TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology offers a full range of solutions and services or strategies for investigating therapeutic strategies that for target tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), helping researchers successfully achieve their research goals.
Macrophages in the tumor microenvironment, which we collectively refer to as tumor-associated macrophages (TAMs). Depending on the phenotype and function, TAMs are classified into tumor suppressor M1-like macrophages and tumor promoting M2-like macrophages. Studies have shown that TAMs in most tumor tissues exhibit an M2-like macrophage phenotype, promote tumor growth, metastasis and recurrence, and are especially closely associated with tumor vascular and lymphatic vessel production. The study of how to target tumor-associated macrophages for the purpose of tumor treatment is a hot topic in tumor immunology research.
Fig. 1 An overview of TAMs in the TME. (Zhou K, et al., 2020)
Although tumor-associated macrophages (TAMs) related studies have yielded positive antitumor results, further studies are still needed to better characterize TAMs, which will facilitate the further establishment of new strategies for tumor treatment. Here, Alfa Oncology has established an innovative tumor microenvironment center technology platform and is developing several technologies designed to help global collaborators develop therapeutic strategies targeting tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) with the hope of informing clinical applications.
Currently, Alfa Oncology is focused on targeting tumor-associated macrophages (TAMs) for key therapeutic strategies including but not limited to the following, so if you have any questions, please do not hesitate to contact us.
- Exclusion of TAMs (targeting CSF1-CSF1R signaling pathway)
- Inhibition of TAMs recruitment (targeting CCL2-CCR2 signaling pathway)
- Reprogramming of TAMs
- Blocking the CD47-SIRPα axis
- Toll-like receptor agonists
- PI3K inhibitors
Note: The key strategies we focus on are always up to date, please contact us by email for more up-to-date and relevant information.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.
- Zhou K, Cheng T, Zhan J, et al. Targeting tumor-associated macrophages in the tumor microenvironment[J]. Oncology Letters, 2020, 20(5):234.